0001415889-23-016329.txt : 20231212
0001415889-23-016329.hdr.sgml : 20231212
20231212185741
ACCESSION NUMBER: 0001415889-23-016329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231208
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thurman Alex R.
CENTRAL INDEX KEY: 0001920061
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37463
FILM NUMBER: 231482500
MAIL ADDRESS:
STREET 1: C/O GLAUKOS CORPORATION
STREET 2: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLAUKOS Corp
CENTRAL INDEX KEY: 0001192448
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
BUSINESS PHONE: 949-367-9600
MAIL ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
FORMER COMPANY:
FORMER CONFORMED NAME: GLAUKOS CORP
DATE OF NAME CHANGE: 20020925
4
1
form4-12122023_111237.xml
X0508
4
2023-12-08
0001192448
GLAUKOS Corp
GKOS
0001920061
Thurman Alex R.
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY
ALISO VIEJO
CA
92656
false
true
false
false
SVP & CHIEF FINANCIAL OFFICER
0
Stock Option (Right to Buy)
55.18
2023-12-08
4
A
0
1830
0
A
2032-03-24
Common Stock
1830
21042
D
Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating & Governance Committee determined on December 8, 2023 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.
50% of the portion of the option reported herein will vest and become exercisable in February 2024, and the remaining 50% will vest and become exercisable in November 2024.
Diana Scherer, Attorney-in-Fact
2023-12-12